Abstract
Aberrant activation of Wnt/β-catenin signaling pathway is commonly associated to cancer development. However, molecular mechanisms controlling Wnt/β-catenin signaling pathway have been clarified only in part. Here, we show that β-catenin is differently modulated in patients with multiple sclerosis (MS), displaying that different pharmacological treatments used for clinical MS management cause different nuclear expression levels of β-catenin. Proteins extracted by peripheral blood mononuclear cells were assessed to evaluate the western blot expression levels of β-catenin. Analyzing our results, we realized that β-catenin is totally inhibited by Natalizumab and could have a role in MS management. This could offer new promising studies focused on the possible therapeutic control of β-catenin translocation.
Keywords: Relapsing/remitting multiple sclerosis, first diagnosis patients, Wnt/β-catenin pathway, natalizumab, interferon-beta, neurodegenerative disease.
Current Molecular Medicine
Title:Is β-catenin neutralization cross-involved in the mechanisms mediated by natalizumab action?
Volume: 15 Issue: 10
Author(s): M. Galuppo, E. Mazzon, S. Giacoppo, O. Bereshchenko, S. Bruscoli, C. Riccardi and P. Bramanti
Affiliation:
Keywords: Relapsing/remitting multiple sclerosis, first diagnosis patients, Wnt/β-catenin pathway, natalizumab, interferon-beta, neurodegenerative disease.
Abstract: Aberrant activation of Wnt/β-catenin signaling pathway is commonly associated to cancer development. However, molecular mechanisms controlling Wnt/β-catenin signaling pathway have been clarified only in part. Here, we show that β-catenin is differently modulated in patients with multiple sclerosis (MS), displaying that different pharmacological treatments used for clinical MS management cause different nuclear expression levels of β-catenin. Proteins extracted by peripheral blood mononuclear cells were assessed to evaluate the western blot expression levels of β-catenin. Analyzing our results, we realized that β-catenin is totally inhibited by Natalizumab and could have a role in MS management. This could offer new promising studies focused on the possible therapeutic control of β-catenin translocation.
Export Options
About this article
Cite this article as:
Galuppo M., Mazzon E., Giacoppo S., Bereshchenko O., Bruscoli S., Riccardi C. and Bramanti P., Is β-catenin neutralization cross-involved in the mechanisms mediated by natalizumab action?, Current Molecular Medicine 2015; 15 (10) . https://dx.doi.org/10.2174/1566524016666151123114825
DOI https://dx.doi.org/10.2174/1566524016666151123114825 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nitric Oxide, Peroxynitrite, Peroxynitrous Acid, Nitroxyl, Nitrogen Dioxide, Nitrous Oxide: Biochemical Mechanisms and Bioaction
Current Bioactive Compounds Scope and Applications of Nanomedicines for the Management of Multiple Sclerosis
Current Drug Metabolism Thymic Nurse Cells Participate in Heterotypic Internalization and Repertoire Selection of Immature Thymocytes; Their Removal from the Thymus of Autoimmune Animals May be Important to Disease Etiology
Current Molecular Medicine Effects of Biphenyl Sulfonylamino Methyl Bisphosphonic Acids on Porphyromonas Gingivalis and Cytokine Secretion by Oral Epithelial Cells
Medicinal Chemistry The Emerging Role of the Cannabinoid Receptor Family in Peripheral and Neuro-immune Interactions
Current Drug Targets Tyrosine Kinases as Targets for Anti-Inflammatory Therapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Mechanisms of Mononuclear Phagocyte Recruitment in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Therapeutic Strategy of Erythropoietin in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Polyphenols as Potential Therapeutics for Pain and Inflammation in Spinal Cord Injury
Current Molecular Pharmacology Talking to the Synapse: How Antidepressants Can Target Glial Cells to Reshape Brain Circuits
Current Drug Targets Seeing Genes at Work in the Living Brain with Non-Invasive Molecular Imaging
Current Gene Therapy Mesenchymal Stem Cells of Dental Origin-Their Potential for Antiinflammatory and Regenerative Actions in Brain and Gut Damage
Current Neuropharmacology Potential Crossreactivity of Human Immune Responses Against HCMV Glycoprotein B
Current Drug Discovery Technologies Therapeutical Potential of CB<sub>2</sub> Receptors in Immune-Related Diseases
Current Molecular Pharmacology CD47 in the Immune Response: Role of Thrombospondin and SIRP-α Reverse Signaling
Current Drug Targets Inhibition of Brain Phospholipase A2 by Antimalarial Drugs: Implications for Neuroprotection in Neurological Disorders
Medicinal Chemistry Reviews - Online (Discontinued) Cyano Acrylate Polymers in Medical Applications
Recent Patents on Materials Science The Expanding Role of TNF-Receptor Super Family Member CD40 (tnfrsf5) in Autoimmune Disease: Focus on Th40 Cells
Current Immunology Reviews (Discontinued) Conjugates of Cell Adhesion Peptides for Therapeutics and Diagnostics Against Cancer and Autoimmune Diseases
Current Topics in Medicinal Chemistry The Role of Aryl Hydrocarbon Receptor-Regulated Cytochrome P450 Enzymes in Glioma
Current Pharmaceutical Design